Bruce E Johnson

Bruce E Johnson

UNVERIFIED PROFILE

Are you Bruce E Johnson?   Register this Author

Register author
Bruce E Johnson

Bruce E Johnson

Publications by authors named "Bruce E Johnson"

Are you Bruce E Johnson?   Register this Author

99Publications

3323Reads

34Profile Views

The impact of quantitative CT-based tumor volumetric features on the outcomes of patients with limited stage small cell lung cancer.

Authors:
Sophia C Kamran Thibaud Coroller Nastaran Milani Vishesh Agrawal Elizabeth H Baldini Aileen B Chen Bruce E Johnson David Kozono Idalid Franco Nitish Chopra Roman Zeleznik Hugo J W L Aerts Raymond Mak

Radiat Oncol 2020 Jan 14;15(1):14. Epub 2020 Jan 14.

Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1186/s13014-020-1460-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6961251PMC
January 2020

From clinical specimens to human cancer preclinical models-a journey the NCI-cell line database-25 years later.

Authors:
James L Mulshine Peter Ujhazy Melissa Antman Christine M Burgess Igor Kuzmin Paul A Bunn Bruce E Johnson Jack A Roth Harvey I Pass Sheila M Ross Carolyn R Aldige Ignacio I Wistuba John D Minna

J Cell Biochem 2019 Dec 5. Epub 2019 Dec 5.

Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center, Dallas, Texas.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/jcb.29564DOI Listing
December 2019

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.

Authors:
Robin Guo Lynne D Berry Dara L Aisner Jamie Sheren Theresa Boyle Paul A Bunn Bruce E Johnson David J Kwiatkowski Alexander Drilon Lynette M Sholl Mark G Kris

J Thorac Oncol 2019 Sep 20;14(9):1666-1671. Epub 2019 Jun 20.

Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Weill Cornell Medical College, New York, New York.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2019.06.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708730PMC
September 2019

M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome.

Authors:
Hyesun Park Suzanne E Dahlberg Christine A Lydon Tetsuro Araki Hiroto Hatabu Michael S Rabin Bruce E Johnson Mizuki Nishino

Oncologist 2019 Aug 29;24(8):e749-e754. Epub 2019 Jan 29.

Department of Radiology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts, USA

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1634/theoncologist.2018-0596DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693709PMC
August 2019

Assessment of Deep Natural Language Processing in Ascertaining Oncologic Outcomes From Radiology Reports.

Authors:
Kenneth L Kehl Haitham Elmarakeby Mizuki Nishino Eliezer M Van Allen Eva M Lepisto Michael J Hassett Bruce E Johnson Deborah Schrag

JAMA Oncol 2019 Jul 25. Epub 2019 Jul 25.

Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1001/jamaoncol.2019.1800DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659158PMC
July 2019

Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience.

Authors:
Badi El Osta Madhusmita Behera Sungjin Kim Lynne D Berry Gabriel Sica Rathi N Pillai Taofeek K Owonikoko Mark G Kris Bruce E Johnson David J Kwiatkowski Lynette M Sholl Dara L Aisner Paul A Bunn Fadlo R Khuri Suresh S Ramalingam

J Thorac Oncol 2019 05 5;14(5):876-889. Epub 2019 Feb 5.

Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2019.01.020DOI Listing
May 2019

Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer.

Authors:
Kenneth L Kehl Christopher S Lathan Bruce E Johnson Deborah Schrag

J Natl Cancer Inst 2019 Apr;111(4):431-434

Division of Population Sciences.

View Article

Download full-text PDF

 Source
https://academic.oup.com/jnci/advance-article/doi/10.1093/jn
Publisher Site
http://dx.doi.org/10.1093/jnci/djy202DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449167PMC
April 2019

Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.

Authors:
Sumanta K Pal Michael J Miller Neeraj Agarwal Susan Marina Chang Mariana Chavez-MacGregor Ezra Cohen Suzanne Cole William Dale Catherine S Magid Diefenbach Mary L Disis Robert Dreicer David L Graham N Lynn Henry Joshua Jones Vicki Keedy Heidi D Klepin Merry Jennifer Markham Elizabeth A Mittendorf Carlos Rodriguez-Galindo Michael S Sabel Richard L Schilsky Mario Sznol William D Tap Shannon Neville Westin Bruce E Johnson

J Clin Oncol 2019 Apr 31;37(10):834-849. Epub 2019 Jan 31.

17 Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.18.02037DOI Listing
April 2019

Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib.

Authors:
Tomoyuki Hida Suzanne E Dahlberg Christine A Lydon Hiroto Hatabu Bruce E Johnson Mark M Awad Mizuki Nishino

J Thorac Imaging 2019 Apr 12. Epub 2019 Apr 12.

Departments of Radiology.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/RTI.0000000000000413DOI Listing
April 2019

Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.

Authors:
Biagio Ricciuti Sasha Kravets Suzanne E Dahlberg Renato Umeton Adem Albayrak Safiya J Subegdjo Bruce E Johnson Mizuki Nishino Lynette M Sholl Mark M Awad

J Immunother Cancer 2019 Mar 28;7(1):87. Epub 2019 Mar 28.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02215, USA.

View Article

Download full-text PDF

 Source
https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0
Publisher Site
http://dx.doi.org/10.1186/s40425-019-0572-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437848PMC
March 2019

Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome.

Authors:
Tetsuro Araki Suzanne E Dahlberg Tomoyuki Hida Christine A Lydon Michael S Rabin Hiroto Hatabu Bruce E Johnson Mizuki Nishino

Eur J Radiol Open 2019 29;6:128-131. Epub 2019 Mar 29.

Department of Radiology, Brigham and Women's Hospital, 73 Francis St., Boston, MA, 02115 USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ejro.2019.03.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444119PMC
March 2019

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.

Authors:
Leora Horn Joshua Bauml Patrick M Forde Keith L Davis Nathaniel J Myall Medha Sasane Anand Dalal Ken Culver Antoinette J Wozniak Christina S Baik Alex Mutebi Pingkuan Zhang Heather A Wakelee Bruce E Johnson

Lung Cancer 2019 02 6;128:74-90. Epub 2018 Dec 6.

Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S01695002183068
Publisher Site
http://dx.doi.org/10.1016/j.lungcan.2018.12.003DOI Listing
February 2019

Review: Thyroid hormone therapy does not improve QoL or symptoms in subclinical hypothyroidism.

Authors:
Bruce E Johnson

Ann Intern Med 2019 02;170(4):JC17

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.7326/ACPJ201902190-017DOI Listing
February 2019

Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer.

Authors:
Ibiayi Dagogo-Jack Pablo Martinez Beow Y Yeap Chiara Ambrogio Lorin A Ferris Christine Lydon Tom Nguyen Nicholas A Jessop A John Iafrate Bruce E Johnson Jochen K Lennerz Alice T Shaw Mark M Awad

Clin Cancer Res 2019 01 17;25(1):158-165. Epub 2018 Sep 17.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-2062DOI Listing
January 2019

Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm.

Authors:
Mizuki Nishino Satoshi Wakai Tomoyuki Hida Suzanne E Dahlberg Masahiro Ozaki Hiroto Hatabu Hisashi Tachizaki Bruce E Johnson

Eur J Radiol 2018 Dec 23;109:68-76. Epub 2018 Oct 23.

Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, 450 Brookline Ave., Boston, MA 02215, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ejrad.2018.10.014DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6294464PMC
December 2018

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.

Authors:
Livnat Jerby-Arnon Parin Shah Michael S Cuoco Christopher Rodman Mei-Ju Su Johannes C Melms Rachel Leeson Abhay Kanodia Shaolin Mei Jia-Ren Lin Shu Wang Bokang Rabasha David Liu Gao Zhang Claire Margolais Orr Ashenberg Patrick A Ott Elizabeth I Buchbinder Rizwan Haq F Stephen Hodi Genevieve M Boland Ryan J Sullivan Dennie T Frederick Benchun Miao Tabea Moll Keith T Flaherty Meenhard Herlyn Russell W Jenkins Rohit Thummalapalli Monika S Kowalczyk Israel Cañadas Bastian Schilling Adam N R Cartwright Adrienne M Luoma Shruti Malu Patrick Hwu Chantale Bernatchez Marie-Andrée Forget David A Barbie Alex K Shalek Itay Tirosh Peter K Sorger Kai Wucherpfennig Eliezer M Van Allen Dirk Schadendorf Bruce E Johnson Asaf Rotem Orit Rozenblatt-Rosen Levi A Garraway Charles H Yoon Benjamin Izar Aviv Regev

Cell 2018 11;175(4):984-997.e24

Broad Institute of MIT and Harvard, Cambridge, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA; Ludwig Center for Cancer Research at MIT, Boston, MA, USA; Massachusetts Institute of Technology, Department of Biology, Cambridge, MA, USA.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S00928674183117
Publisher Site
http://dx.doi.org/10.1016/j.cell.2018.09.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410377PMC
November 2018

2018 ASCO Presidential Address: "Delivering Discoveries: Expanding the Reach of Precision Medicine".

Authors:
Bruce E Johnson

J Clin Oncol 2018 10 30;36(29):2899-2903. Epub 2018 Aug 30.

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.18.00535DOI Listing
October 2018

A Phase I Trial of Surgical Resection and Intraoperative Hyperthermic Cisplatin and Gemcitabine for Pleural Mesothelioma.

Authors:
Bryan M Burt William G Richards Hyun-Sung Lee Sylvia Bartel Marcelo C Dasilva Ritu R Gill Michael T Jaklitsch Bruce E Johnson Scott J Swanson Raphael Bueno David J Sugarbaker

J Thorac Oncol 2018 09 9;13(9):1400-1409. Epub 2018 May 9.

Department of Surgery, Division of General Thoracic Surgery, Baylor College of Medicine, Houston, Texas. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2018.04.032DOI Listing
September 2018

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine.

Authors:
Andrew J Aguirre Jonathan A Nowak Nicholas D Camarda Richard A Moffitt Arezou A Ghazani Mehlika Hazar-Rethinam Srivatsan Raghavan Jaegil Kim Lauren K Brais Dorisanne Ragon Marisa W Welch Emma Reilly Devin McCabe Lori Marini Kristin Anderka Karla Helvie Nelly Oliver Ana Babic Annacarolina Da Silva Brandon Nadres Emily E Van Seventer Heather A Shahzade Joseph P St Pierre Kelly P Burke Thomas Clancy James M Cleary Leona A Doyle Kunal Jajoo Nadine J McCleary Jeffrey A Meyerhardt Janet E Murphy Kimmie Ng Anuj K Patel Kimberly Perez Michael H Rosenthal Douglas A Rubinson Marvin Ryou Geoffrey I Shapiro Ewa Sicinska Stuart G Silverman Rebecca J Nagy Richard B Lanman Deborah Knoerzer Dean J Welsch Matthew B Yurgelun Charles S Fuchs Levi A Garraway Gad Getz Jason L Hornick Bruce E Johnson Matthew H Kulke Robert J Mayer Jeffrey W Miller Paul B Shyn David A Tuveson Nikhil Wagle Jen Jen Yeh William C Hahn Ryan B Corcoran Scott L Carter Brian M Wolpin

Cancer Discov 2018 09 14;8(9):1096-1111. Epub 2018 Jun 14.

Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-18-0275DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192263PMC
September 2018

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.

Authors:
David Planchard Bruce E Johnson

Arch Pathol Lab Med 2018 07 12;142(7):796-797. Epub 2018 Apr 12.

From the Department of Medical Oncology, Gustave Roussy, Villejuif, France (Dr Planchard); and the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, (Dr Johnson).

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.5858/arpa.2018-0088-EDDOI Listing
July 2018

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2).

Authors:
Dara L Aisner Lynette M Sholl Lynne D Berry Michael R Rossi Heidi Chen Junya Fujimoto Andre L Moreira Suresh S Ramalingam Liza C Villaruz Gregory A Otterson Eric Haura Katerina Politi Bonnie Glisson Jeremy Cetnar Edward B Garon Joan Schiller Saiama N Waqar Lecia V Sequist Julie Brahmer Yu Shyr Kelly Kugler Ignacio I Wistuba Bruce E Johnson John D Minna Mark G Kris Paul A Bunn David J Kwiatkowski

Clin Cancer Res 2018 03 7;24(5):1038-1047. Epub 2017 Dec 7.

Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-2289DOI Listing
March 2018

Pooled RCTs: In postmenopausal women, hormone therapy for 6 to 7 years did not affect mortality at 18 years.

Authors:
Bruce E Johnson Cynda Ann Johnson

Ann Intern Med 2018 01;168(2):JC4

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.7326/ACPJC-2018-168-2-004DOI Listing
January 2018

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.

Authors:
Rathi N Pillai Madhusmita Behera Lynne D Berry Mike R Rossi Mark G Kris Bruce E Johnson Paul A Bunn Suresh S Ramalingam Fadlo R Khuri

Cancer 2017 Nov 25;123(21):4099-4105. Epub 2017 Jul 25.

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.30869DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5650517PMC
November 2017

Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Authors:
David Planchard Egbert F Smit Harry J M Groen Julien Mazieres Benjamin Besse Åslaug Helland Vanessa Giannone Anthony M D'Amelio Pingkuan Zhang Bijoyesh Mookerjee Bruce E Johnson

Lancet Oncol 2017 10 11;18(10):1307-1316. Epub 2017 Sep 11.

Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S1470-2045(17)30679-4DOI Listing
October 2017

Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib.

Authors:
Mizuki Nishino Adrian G Sacher Leena Gandhi Zhao Chen Esra Akbay Andriy Fedorov Carl F Westin Hiroto Hatabu Bruce E Johnson Peter Hammerman Kwok-Kin Wong

Eur J Radiol 2017 Mar 26;88:15-20. Epub 2016 Dec 26.

Department of Medical Oncology and Department of Medicine Dana-Farber Cancer Institute and Brigham and Women's Hospital 450 Brookline Ave., Boston MA, 02215, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ejrad.2016.12.028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560072PMC
March 2017

An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC).

Authors:
Mark M Awad Quincy S-C Chu Leena Gandhi Joe J Stephenson Ramaswamy Govindan Daniel S Bradford Philip D Bonomi David M Ellison Keith D Eaton Holger Fritsch Gerd Munzert Bruce E Johnson Mark A Socinski

Lung Cancer 2017 02 30;104:126-130. Epub 2016 Dec 30.

University of Pittsburgh, Pittsburgh, PA, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2016.12.019DOI Listing
February 2017

Guideline: An expert panel found that calcium intake is safe from a cardiovascular perspective.

Authors:
Bruce E Johnson Elvis R Pagan

Ann Intern Med 2017 02;166(4):JC16

Virginia Tech Carilion School of MedicineRoanoke, Virginia, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.7326/ACPJC-2017-166-4-016DOI Listing
February 2017

Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.

Authors:
Curtis R Chong Magda Bahcall Marzia Capelletti Takayuki Kosaka Dalia Ercan Taebo Sim Lynette M Sholl Mizuki Nishino Bruce E Johnson Nathanael S Gray Pasi A Jänne

Clin Cancer Res 2017 Jan 1;23(1):204-213. Epub 2016 Jul 1.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1601DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5203969PMC
January 2017

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.

Authors:
Masahiko Yanagita Amanda J Redig Cloud P Paweletz Suzanne E Dahlberg Allison O'Connell Nora Feeney Myriam Taibi David Boucher Geoffrey R Oxnard Bruce E Johnson Daniel B Costa David M Jackman Pasi A Jänne

Clin Cancer Res 2016 Dec 8;22(24):6010-6020. Epub 2016 Jun 8.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0909DOI Listing
December 2016

Divide and Conquer to Treat Lung Cancer.

Authors:
Bruce E Johnson

N Engl J Med 2016 11 8;375(19):1892-1893. Epub 2016 Oct 8.

From the Department of Medical Oncology, Dana-Farber Cancer Institute, and the Department of Medicine, Brigham and Women's Hospital - both in Boston.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1056/NEJMe1611003DOI Listing
November 2016

Institutional implementation of clinical tumor profiling on an unselected cancer population.

Authors:
Lynette M Sholl Khanh Do Priyanka Shivdasani Ethan Cerami Adrian M Dubuc Frank C Kuo Elizabeth P Garcia Yonghui Jia Phani Davineni Ryan P Abo Trevor J Pugh Paul van Hummelen Aaron R Thorner Matthew Ducar Alice H Berger Mizuki Nishino Katherine A Janeway Alanna Church Marian Harris Lauren L Ritterhouse Joshua D Campbell Vanesa Rojas-Rudilla Azra H Ligon Shakti Ramkissoon James M Cleary Ursula Matulonis Geoffrey R Oxnard Richard Chao Vanessa Tassell James Christensen William C Hahn Philip W Kantoff David J Kwiatkowski Bruce E Johnson Matthew Meyerson Levi A Garraway Geoffrey I Shapiro Barrett J Rollins Neal I Lindeman Laura E MacConaill

JCI Insight 2016 11 17;1(19):e87062. Epub 2016 Nov 17.

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1172/jci.insight.87062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111542PMC
November 2016

Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial.

Authors:
Amanda J Redig Daniel B Costa Myriam Taibi David Boucher Bruce E Johnson Pasi A Jänne David M Jackman

JAMA Oncol 2016 Sep;2(9):1240-2

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1001/jamaoncol.2016.1304DOI Listing
September 2016

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.

Authors:
David Planchard Benjamin Besse Harry J M Groen Pierre-Jean Souquet Elisabeth Quoix Christina S Baik Fabrice Barlesi Tae Min Kim Julien Mazieres Silvia Novello James R Rigas Allison Upalawanna Anthony M D'Amelio Pingkuan Zhang Bijoyesh Mookerjee Bruce E Johnson

Lancet Oncol 2016 Jul 6;17(7):984-993. Epub 2016 Jun 6.

Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S1470-2045(16)30146-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4993103PMC
July 2016

Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.

Authors:
David Planchard Tae Min Kim Julien Mazieres Elisabeth Quoix Gregory Riely Fabrice Barlesi Pierre-Jean Souquet Egbert F Smit Harry J M Groen Ronan J Kelly B C Cho Mark A Socinski Lini Pandite Christine Nase Bo Ma Anthony D'Amelio Bijoyesh Mookerjee C Martin Curtis Bruce E Johnson

Lancet Oncol 2016 05 11;17(5):642-50. Epub 2016 Apr 11.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S1470-2045(16)00077-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5006181PMC
May 2016

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.

Authors:
Monique B Nilsson Uma Giri Jayanthi Gudikote Ximing Tang Wei Lu Hai Tran Youhong Fan Andrew Koo Lixia Diao Pan Tong Jing Wang Roy Herbst Bruce E Johnson Andy Ryan Alan Webster Philip Rowe Ignacio I Wistuba John V Heymach

Clin Cancer Res 2016 Apr 17;22(8):1940-50. Epub 2015 Nov 17.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1994DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4834253PMC
April 2016

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs.

Authors:
Jessica J Lin Stephanie Cardarella Christine A Lydon Suzanne E Dahlberg David M Jackman Pasi A Jänne Bruce E Johnson

J Thorac Oncol 2016 Apr 25;11(4):556-65. Epub 2015 Dec 25.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.jtho.2015.12.103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979601PMC
April 2016

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.

Authors:
Tilak K Sundaresan Lecia V Sequist John V Heymach Gregory J Riely Pasi A Jänne Walter H Koch James P Sullivan Douglas B Fox Robert Maher Alona Muzikansky Andrew Webb Hai T Tran Uma Giri Martin Fleisher Helena A Yu Wen Wei Bruce E Johnson Thomas A Barber John R Walsh Jeffrey A Engelman Shannon L Stott Ravi Kapur Shyamala Maheswaran Mehmet Toner Daniel A Haber

Clin Cancer Res 2016 Mar 7;22(5):1103-10. Epub 2015 Oct 7.

Massachusetts General Hospital Cancer Center, Boston, Massachusetts. Department of Medicine, Harvard Medical School, Boston, Massachusetts. Howard Hughes Medical Institute, Chevy Chase, Maryland.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1031DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4775471PMC
March 2016

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium.

Authors:
Conor E Steuer Madhusmita Behera Lynne Berry Sungjin Kim Michael Rossi Gabriel Sica Taofeek K Owonikoko Bruce E Johnson Mark G Kris Paul A Bunn Fadlo R Khuri Edward B Garon Suresh S Ramalingam

Cancer 2016 Mar 22;122(5):766-72. Epub 2015 Dec 22.

Winship Cancer Institute, Emory University, Atlanta, Georgia.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.29812DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5038591PMC
March 2016

Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.

Authors:
Mizuki Nishino Suzanne E Dahlberg Linnea E Fulton Subba R Digumarthy Hiroto Hatabu Bruce E Johnson Lecia V Sequist

Acad Radiol 2016 Mar 8;23(3):329-36. Epub 2016 Jan 8.

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.acra.2015.11.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744559PMC
March 2016

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.

Authors:
Shohei Koyama Esra A Akbay Yvonne Y Li Grit S Herter-Sprie Kevin A Buczkowski William G Richards Leena Gandhi Amanda J Redig Scott J Rodig Hajime Asahina Robert E Jones Meghana M Kulkarni Mari Kuraguchi Sangeetha Palakurthi Peter E Fecci Bruce E Johnson Pasi A Janne Jeffrey A Engelman Sidharta P Gangadharan Daniel B Costa Gordon J Freeman Raphael Bueno F Stephen Hodi Glenn Dranoff Kwok-Kin Wong Peter S Hammerman

Nat Commun 2016 Feb 17;7:10501. Epub 2016 Feb 17.

Depatment of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/ncomms10501DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757784PMC
February 2016

Emerging gene mutation targets in lung cancer.

Authors:
Bruce E Johnson

Clin Adv Hematol Oncol 2015 Dec;13(12):812-4

Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
December 2015

Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets.

Authors:
Priscilla K Brastianos Scott L Carter Sandro Santagata Daniel P Cahill Amaro Taylor-Weiner Robert T Jones Eliezer M Van Allen Michael S Lawrence Peleg M Horowitz Kristian Cibulskis Keith L Ligon Josep Tabernero Joan Seoane Elena Martinez-Saez William T Curry Ian F Dunn Sun Ha Paek Sung-Hye Park Aaron McKenna Aaron Chevalier Mara Rosenberg Frederick G Barker Corey M Gill Paul Van Hummelen Aaron R Thorner Bruce E Johnson Mai P Hoang Toni K Choueiri Sabina Signoretti Carrie Sougnez Michael S Rabin Nancy U Lin Eric P Winer Anat Stemmer-Rachamimov Matthew Meyerson Levi Garraway Stacey Gabriel Eric S Lander Rameen Beroukhim Tracy T Batchelor Jose Baselga David N Louis Gad Getz William C Hahn

Cancer Discov 2015 Nov 26;5(11):1164-1177. Epub 2015 Sep 26.

Department of Medical Oncology, Brigham and Women's Hospital, Harvard Medical School - all in Boston.

View Article

Download full-text PDF

 Source
http://cancerdiscovery.aacrjournals.org/content/early/2015/0
Web Search
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8290.CD-15-0369DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916970PMC
November 2015

Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer.

Authors:
Peter C Lo Suzanne E Dahlberg Mizuki Nishino Bruce E Johnson Lecia V Sequist David M Jackman Pasi A Jänne Geoffrey R Oxnard

Cancer 2015 Aug 15;121(15):2570-7. Epub 2015 Apr 15.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.29397DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4525718PMC
August 2015

Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival.

Authors:
Mizuki Nishino Stephanie Cardarella Suzanne E Dahlberg Tetsuro Araki Christine Lydon David M Jackman Michael S Rabin Hiroto Hatabu Bruce E Johnson

Eur J Radiol 2015 May 7;84(5):998-1004. Epub 2015 Feb 7.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ejrad.2015.01.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397190PMC
May 2015

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.

Authors:
Lynette M Sholl Dara L Aisner Marileila Varella-Garcia Lynne D Berry Dora Dias-Santagata Ignacio I Wistuba Heidi Chen Junya Fujimoto Kelly Kugler Wilbur A Franklin A John Iafrate Marc Ladanyi Mark G Kris Bruce E Johnson Paul A Bunn John D Minna David J Kwiatkowski

J Thorac Oncol 2015 May;10(5):768-777

Department of Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0000000000000516DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4410843PMC
May 2015

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium.

Authors:
Liza C Villaruz Mark A Socinski Shira Abberbock Lynne D Berry Bruce E Johnson David J Kwiatkowski A John Iafrate Marileila Varella-Garcia Wilbur A Franklin D Ross Camidge Lecia V Sequist Eric B Haura Mark Ladanyi Brenda F Kurland Kelly Kugler John D Minna Paul A Bunn Mark G Kris

Cancer 2015 Feb 1;121(3):448-56. Epub 2014 Oct 1.

University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.29042DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305000PMC
February 2015

A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.

Authors:
David M Jackman Leigh A Cioffredi Lorraine Jacobs Farhana Sharmeen Linda K Morse Joan Lucca Scott R Plotkin Paul J Marcoux Michael S Rabin Thomas J Lynch Bruce E Johnson Santosh Kesari

Oncotarget 2015 Feb;6(6):4527-36

Department of Neurosciences, Translational Neuro-Oncology Laboratories, Moores UCSD Cancer Center, University of California, San Diego, La Jolla CA, USA.

View Article

Download full-text PDF

 Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414209PMC
http://dx.doi.org/10.18632/oncotarget.2886DOI Listing
February 2015

Chemotherapy for locally advanced and metastatic pulmonary carcinoid tumors.

Authors:
Curtis R Chong Lori J Wirth Mizuki Nishino Aileen B Chen Lynette M Sholl Matthew H Kulke Ciaran J McNamee Pasi A Jänne Bruce E Johnson

Lung Cancer 2014 Nov 27;86(2):241-6. Epub 2014 Aug 27.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, United States. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2014.08.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293119PMC
November 2014

Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).

Authors:
Fairooz Kabbinavar Louis Fehrenbacher John Hainsworth Saifuddin Kasubhai Bruce Kressel Thomas Marsland Taral Patel Mark Rubin Leonard White James Chih-Hsin Yang Barbara Klughammer Dawn Colburn Vincent Miller Bruce E Johnson

J Thorac Oncol 2014 Sep;9(9):1411-7

*University of California Los Angeles, Los Angeles, CA; †Kaiser Permanente Northern CA, Antioch, CA; ‡Sarah Cannon Research Institute, Nashville, TN; §Northwest Medical Specialties, Tacoma, WA; ‖Sibley Memorial Hospital, Washington, DC; ¶Integrated Community Oncology Network, Jacksonville, FL; #The Mark H. Zangmeister Center, Columbus, OH; **Florida Cancer Specialists, Bonita Springs, FL; ††Arch Medical Services Inc., The Center for Cancer Care and Research, Saint Louis, MO; ‡‡National Taiwan University, Taipei, Taiwan; §§F. Hoffmann-La Roche Ltd., Basel, Switzerland; ‖‖Genentech Inc., South San Francisco, CA; ¶¶Weill Cornell Medical College and Thoracic Oncology Service, New York, NY; and ##Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0000000000000274DOI Listing
September 2014

Realizing the potential of plasma genotyping in an age of genotype-directed therapies.

Authors:
Jason J Luke Geoffrey R Oxnard Cloud P Paweletz D Ross Camidge John V Heymach David B Solit Bruce E Johnson

J Natl Cancer Inst 2014 Aug 8;106(8). Epub 2014 Aug 8.

Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (JJL, GRO, CPP, BEJ), Memorial Sloan-Kettering Cancer Center, New York, NY (DBS), University of Colorado Cancer Center, Denver, CO (DRC); The University of Texas MD Anderson Cancer Center, Houston, TX (JVH).

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1093/jnci/dju214DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6281080PMC
August 2014

Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer.

Authors:
Ravi B Parikh Angel M Cronin David E Kozono Geoffrey R Oxnard Raymond H Mak David M Jackman Peter C Lo Elizabeth H Baldini Bruce E Johnson Aileen B Chen

Int J Radiat Oncol Biol Phys 2014 Jul 24;89(4):880-7. Epub 2014 May 24.

Dana-Farber Cancer Institute, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.ijrobp.2014.04.007DOI Listing
July 2014

Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience.

Authors:
Suzanne E Dahlberg Geoffrey I Shapiro Jeffrey W Clark Bruce E Johnson

J Natl Cancer Inst 2014 Jul 24;106(7). Epub 2014 Jun 24.

Affiliations of authors: Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA (SED); Department of Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA (GIS, BEJ); Department of Hematology and Oncology (JWC) and Department of Medicine (JWC), Massachusetts General Hospital, Boston, MA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1093/jnci/dju163DOI Listing
July 2014

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:
Mark G Kris Bruce E Johnson Lynne D Berry David J Kwiatkowski A John Iafrate Ignacio I Wistuba Marileila Varella-Garcia Wilbur A Franklin Samuel L Aronson Pei-Fang Su Yu Shyr D Ross Camidge Lecia V Sequist Bonnie S Glisson Fadlo R Khuri Edward B Garon William Pao Charles Rudin Joan Schiller Eric B Haura Mark Socinski Keisuke Shirai Heidi Chen Giuseppe Giaccone Marc Ladanyi Kelly Kugler John D Minna Paul A Bunn

JAMA 2014 May;311(19):1998-2006

University of Colorado Cancer Center Denver, Aurora.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1001/jama.2014.3741DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4163053PMC
May 2014

State of the art: Response assessment in lung cancer in the era of genomic medicine.

Authors:
Mizuki Nishino Hiroto Hatabu Bruce E Johnson Theresa C McLoud

Radiology 2014 Apr;271(1):6-27

From the Departments of Imaging (M.N.) and Medical Oncology (B.E.J.), Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215; Departments of Radiology (M.N., H.H.) and Medicine (B.E.J.), Brigham and Women's Hospital, Boston, Mass; and Department of Radiology, Massachusetts General Hospital, Boston, Mass (T.C.M.).

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1148/radiol.14122524DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263630PMC
April 2014

Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression.

Authors:
Mizuki Nishino Suzanne E Dahlberg Stephanie Cardarella David M Jackman Michael S Rabin Nikhil H Ramaiya Hiroto Hatabu Pasi A Jänne Bruce E Johnson

Cancer 2013 Nov 6;119(21):3761-8. Epub 2013 Aug 6.

Department of Radiology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.28290DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817609PMC
November 2013

Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization.

Authors:
Jeonghee Cho Liang Chen Naveen Sangji Takafumi Okabe Kimio Yonesaka Joshua M Francis Richard J Flavin William Johnson Jihyun Kwon Soyoung Yu Heidi Greulich Bruce E Johnson Michael J Eck Pasi A Jänne Kwok-Kin Wong Matthew Meyerson

Cancer Res 2013 Nov 24;73(22):6770-9. Epub 2013 Sep 24.

Authors' Affiliations: Departments of Medical Oncology and Cancer Biology; Center for Cancer Genome Discovery, Lowe Center for Thoracic Oncology, and Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute; Departments of Medicine, Brigham and Women's Hospital; Departments of Biological Chemistry and Molecular Pharmacology and Pathology, Harvard Medical School, Boston, Massachusetts; Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea; and The Broad Institute of Harvard and MIT, Cambridge, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1145DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903789PMC
November 2013

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

Authors:
Bruce E Johnson Fairooz Kabbinavar Louis Fehrenbacher John Hainsworth Saifuddin Kasubhai Bruce Kressel Chin-Yu Lin Thomas Marsland Taral Patel Jonathan Polikoff Mark Rubin Leonard White James Chih-Hsin Yang Chris Bowden Vincent Miller

J Clin Oncol 2013 Nov 7;31(31):3926-34. Epub 2013 Oct 7.

Bruce E. Johnson, Dana-Farber Cancer Institute, Boston, MA; Fairooz Kabbinavar, University of California Los Angeles, Translational Oncology Research International, Los Angeles; Louis Fehrenbacher, Kaiser Permanente Northern California, Vallejo; Chin-Yu Lin and Chris Bowden, Genentech, South San Francisco; Jonathan Polikoff, Southern California Permanente Medical Group, San Diego, CA; John Hainsworth, Sarah Cannon Research Institute, Nashville, TN; Saifuddin Kasubhai, Northwest Medical Specialties, Tacoma, WA; Bruce Kressel, Sibley Memorial Hospital, Washington, DC; Thomas Marsland, Integrated Community Oncology Network, Orange Park; Mark Rubin, Florida Cancer Specialists, Fort Myers, FL; Taral Patel, The Mark H. Zangmeister Center, Columbus, OH; Leonard White, Arch Medical Services, The Center for Cancer Care and Research, Saint Louis, MO; Vincent Miller, Weill Cornell Medical College and Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; and James Chih-Hsin Yang, National Taiwan University, Taipei, Taiwan.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2012.47.3983DOI Listing
November 2013

Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung.

Authors:
Andrew M Brunner Daniel B Costa Rebecca S Heist Elizabeth Garcia Neal I Lindeman Lynette M Sholl Geoffrey R Oxnard Bruce E Johnson Peter S Hammerman

J Thorac Oncol 2013 Nov;8(11):1434-7

*Massachusetts General Hospital Cancer Center, Boston, Massachusetts; †Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts; ‡Department of Pathology and Center for Advanced Molecular Diagnostics, Brigham and Women's Hospital, Boston, Massachusetts; and §Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0b013e3182a47162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3801424PMC
November 2013

The impact of genomic changes on treatment of lung cancer.

Authors:
Stephanie Cardarella Bruce E Johnson

Am J Respir Crit Care Med 2013 Oct;188(7):770-5

1 Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1164/rccm.201305-0843PPDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3826273PMC
October 2013

Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI.

Authors:
Mizuki Nishino Suzanne E Dahlberg Stephanie Cardarella David M Jackman Michael S Rabin Hiroto Hatabu Pasi A Jänne Bruce E Johnson

J Thorac Oncol 2013 Aug;8(8):1059-68

Department of Imaging, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0b013e318294c909DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3714311PMC
August 2013

Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Authors:
Stephanie Cardarella Atsuko Ogino Mizuki Nishino Mohit Butaney Jeanne Shen Christine Lydon Beow Y Yeap Lynette M Sholl Bruce E Johnson Pasi A Jänne

Clin Cancer Res 2013 Aug 5;19(16):4532-40. Epub 2013 Jul 5.

Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

 Source
http://clincancerres.aacrjournals.org/content/19/16/4532.ful
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-13-0657DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762878PMC
August 2013

RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.

Authors:
Mizuki Nishino Stephanie Cardarella David M Jackman Nikhil H Ramaiya Michael S Rabin Hiroto Hatabu Pasi A Jänne Bruce E Johnson

AJR Am J Roentgenol 2013 Jul;201(1):W64-71

Department of Imaging Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston MA 02215, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.2214/AJR.12.9668DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731976PMC
July 2013

Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.

Authors:
Junya Zhu Dhruv B Sharma Aileen B Chen Bruce E Johnson Jane C Weeks Deborah Schrag

Cancer 2013 Jun 5;119(11):2048-60. Epub 2013 Apr 5.

Center for Patient Safety, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.28022DOI Listing
June 2013

Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts.

Authors:
Stephanie Cardarella Bruce E Johnson

J Natl Cancer Inst 2013 May 17;105(9):589-90. Epub 2013 Apr 17.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1093/jnci/djt085DOI Listing
May 2013

Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors.

Authors:
Mizuki Nishino Stephanie Cardarella Suzanne E Dahlberg David M Jackman Nikhil H Ramaiya Hiroto Hatabu Michael S Rabin Pasi A Jänne Bruce E Johnson

Lung Cancer 2013 Mar 14;79(3):283-8. Epub 2012 Dec 14.

Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2012.11.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580850PMC
March 2013

Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.

Authors:
Geoffrey R Oxnard Peter C Lo Mizuki Nishino Suzanne E Dahlberg Neal I Lindeman Mohit Butaney David M Jackman Bruce E Johnson Pasi A Jänne

J Thorac Oncol 2013 Feb;8(2):179-84

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0b013e3182779d18DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549533PMC
February 2013

The introduction of systematic genomic testing for patients with non-small-cell lung cancer.

Authors:
Stephanie Cardarella Taylor M Ortiz Victoria A Joshi Mohit Butaney David M Jackman David J Kwiatkowski Beow Y Yeap Pasi A Jänne Neal I Lindeman Bruce E Johnson

J Thorac Oncol 2012 Dec;7(12):1767-1774

Department of Medical Oncology, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts; Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0b013e3182745bcbDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500523PMC
December 2012

Unsuspected pulmonary embolism in lung cancer patients: comparison of clinical characteristics and outcome with suspected pulmonary embolism.

Authors:
Atul B Shinagare Yuka Okajima Geoffrey R Oxnard Pamela J Dipiro Bruce E Johnson Hiroto Hatabu Mizuki Nishino

Lung Cancer 2012 Nov 7;78(2):161-6. Epub 2012 Sep 7.

Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave., Boston, MA 02215, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2012.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605722PMC
November 2012

Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.

Authors:
Vassiliki A Papadimitrakopoulou Jean-Charles Soria Annette Jappe Valentine Jehl Judith Klimovsky Bruce E Johnson

J Thorac Oncol 2012 Oct;7(10):1594-601

University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA. vpapadim@ mdanderson.org

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S15560864153260
Publisher Site
http://dx.doi.org/10.1097/JTO.0b013e3182614835DOI Listing
October 2012

Adjuvant chemotherapy for surgically resected non-small cell lung cancer.

Authors:
Stephanie Heon Bruce E Johnson

J Thorac Cardiovasc Surg 2012 Sep 13;144(3):S39-42. Epub 2012 Apr 13.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana Building 1234, Boston, MA 02215, USA.

View Article

Download full-text PDF

 Source
https://linkinghub.elsevier.com/retrieve/pii/S00225223120035
Publisher Site
http://dx.doi.org/10.1016/j.jtcvs.2012.03.039DOI Listing
September 2012

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.

Authors:
Marcin Imielinski Alice H Berger Peter S Hammerman Bryan Hernandez Trevor J Pugh Eran Hodis Jeonghee Cho James Suh Marzia Capelletti Andrey Sivachenko Carrie Sougnez Daniel Auclair Michael S Lawrence Petar Stojanov Kristian Cibulskis Kyusam Choi Luc de Waal Tanaz Sharifnia Angela Brooks Heidi Greulich Shantanu Banerji Thomas Zander Danila Seidel Frauke Leenders Sascha Ansén Corinna Ludwig Walburga Engel-Riedel Erich Stoelben Jürgen Wolf Chandra Goparju Kristin Thompson Wendy Winckler David Kwiatkowski Bruce E Johnson Pasi A Jänne Vincent A Miller William Pao William D Travis Harvey I Pass Stacey B Gabriel Eric S Lander Roman K Thomas Levi A Garraway Gad Getz Matthew Meyerson

Cell 2012 Sep;150(6):1107-20

Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, MA 02142, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.cell.2012.08.029DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3557932PMC
September 2012

ACP Journal Club. Review: teriparatide reduces fractures in postmenopausal women with osteoporosis.

Authors:
Bruce E Johnson

Ann Intern Med 2012 Sep;157(6):JC3-4

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.7326/0003-4819-157-6-201209180-02004DOI Listing
September 2012

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Authors:
Stephanie Heon Beow Y Yeap Neal I Lindeman Victoria A Joshi Mohit Butaney Gregory J Britt Daniel B Costa Michael S Rabin David M Jackman Bruce E Johnson

Clin Cancer Res 2012 Aug 25;18(16):4406-14. Epub 2012 Jun 25.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

View Article

Download full-text PDF

 Source
http://clincancerres.aacrjournals.org/content/early/2012/07/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-12-0357DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682221PMC
August 2012

Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening.

Authors:
Pamela M McMahon Chung Yin Kong Bruce E Johnson Milton C Weinstein Jane C Weeks Angela C Tramontano Lauren E Cipriano Colleen Bouzan G Scott Gazelle

Risk Anal 2012 Jul;32 Suppl 1:S117-24

Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac Street, Boston, MA 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/j.1539-6924.2011.01652.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3478757PMC
July 2012

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.

Authors:
Mizuki Nishino Sarah K Cryer Yuka Okajima Lynette M Sholl Hiroto Hatabu Michael S Rabin David M Jackman Bruce E Johnson

Cancer Imaging 2012 Jun 29;12:225-35. Epub 2012 Jun 29.

Department of Radiology, Dana-Farber Cancer Institute and Brigham and Womens Hospital, Boston, MA 02215-5450, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1102/1470-7330.2012.0027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392782PMC
June 2012

Factors associated with smoking abstinence among smokers and recent-quitters with lung and head and neck cancer.

Authors:
Mary E Cooley Qian Wang Bruce E Johnson Paul Catalano Robert I Haddad Raphael Bueno Karen M Emmons

Lung Cancer 2012 May 16;76(2):144-9. Epub 2011 Nov 16.

Dana Farber Cancer Institute, Boston, MA 02115, USA. mary

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2011.10.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322288PMC
May 2012

Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.

Authors:
David R Parkinson Bruce E Johnson George W Sledge

Clin Cancer Res 2012 Feb;18(3):619-24

Nodality, Inc., South San Francisco, California 94080, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2017DOI Listing
February 2012

Cost-effectiveness of computed tomography screening for lung cancer in the United States.

Authors:
Pamela M McMahon Chung Yin Kong Colleen Bouzan Milton C Weinstein Lauren E Cipriano Angela C Tramontano Bruce E Johnson Jane C Weeks G Scott Gazelle

J Thorac Oncol 2011 Nov;6(11):1841-8

Institute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0b013e31822e59b3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202298PMC
November 2011

Patient-reported receipt of and interest in smoking-cessation interventions after a diagnosis of cancer.

Authors:
Mary E Cooley Karen M Emmons Robert Haddad Qian Wang Marshall Posner Raphael Bueno Tiffany-Jen Cohen Bruce E Johnson

Cancer 2011 Jul 10;117(13):2961-9. Epub 2011 Jan 10.

Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1002/cncr.25828DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3314027PMC
July 2011

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.

Authors:
Peter S Hammerman Martin L Sos Alex H Ramos Chunxiao Xu Amit Dutt Wenjun Zhou Lear E Brace Brittany A Woods Wenchu Lin Jianming Zhang Xianming Deng Sang Min Lim Stefanie Heynck Martin Peifer Jeffrey R Simard Michael S Lawrence Robert C Onofrio Helga B Salvesen Danila Seidel Thomas Zander Johannes M Heuckmann Alex Soltermann Holger Moch Mirjam Koker Frauke Leenders Franziska Gabler Silvia Querings Sascha Ansén Elisabeth Brambilla Christian Brambilla Philippe Lorimier Odd Terje Brustugun Aslaug Helland Iver Petersen Joachim H Clement Harry Groen Wim Timens Hannie Sietsma Erich Stoelben Jürgen Wolf David G Beer Ming Sound Tsao Megan Hanna Charles Hatton Michael J Eck Pasi A Janne Bruce E Johnson Wendy Winckler Heidi Greulich Adam J Bass Jeonghee Cho Daniel Rauh Nathanael S Gray Kwok-Kin Wong Eric B Haura Roman K Thomas Matthew Meyerson

Cancer Discov 2011 Jun;1(1):78-89

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/2159-8274.CD-11-0005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3274752PMC
June 2011

The BATTLE trial: personalizing therapy for lung cancer.

Authors:
Edward S Kim Roy S Herbst Ignacio I Wistuba J Jack Lee George R Blumenschein Anne Tsao David J Stewart Marshall E Hicks Jeremy Erasmus Sanjay Gupta Christine M Alden Suyu Liu Ximing Tang Fadlo R Khuri Hai T Tran Bruce E Johnson John V Heymach Li Mao Frank Fossella Merrill S Kies Vassiliki Papadimitrakopoulou Suzanne E Davis Scott M Lippman Waun K Hong

Cancer Discov 2011 Jun 1;1(1):44-53. Epub 2011 Jun 1.

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

 Source
http://cancerdiscovery.aacrjournals.org/content/early/2011/0
Web Search
http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159
Publisher Site
http://dx.doi.org/10.1158/2159-8274.CD-10-0010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211116PMC
June 2011

Imaging of lung cancer in the era of molecular medicine.

Authors:
Mizuki Nishino David M Jackman Hiroto Hatabu Pasi A Jänne Bruce E Johnson Annick D Van den Abbeele

Acad Radiol 2011 Apr 28;18(4):424-36. Epub 2011 Jan 28.

Department of Imaging, Dana-Farber Cancer Institute, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.acra.2010.10.020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380440PMC
April 2011

Haplotypes of estrogen receptor-beta and risk of non-small cell lung cancer in women.

Authors:
Jessica K Paulus Wei Zhou Peter Kraft Bruce E Johnson Xihong Lin David C Christiani

Lung Cancer 2011 Mar 23;71(3):258-63. Epub 2010 Jul 23.

Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2010.06.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988987PMC
March 2011

CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool.

Authors:
Mizuki Nishino Mengye Guo David M Jackman Pamela J DiPiro Jeffrey T Yap Tak K Ho Hiroto Hatabu Pasi A Jänne Annick D Van den Abbeele Bruce E Johnson

Acad Radiol 2011 Jan 30;18(1):54-62. Epub 2010 Oct 30.

Department of Imaging, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Boston, MA 02115, USA.

View Article

Download full-text PDF

 Source
http://linkinghub.elsevier.com/retrieve/pii/S107663321000509
Publisher Site
http://dx.doi.org/10.1016/j.acra.2010.08.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3129593PMC
January 2011

Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Authors:
Stephanie Heon Beow Y Yeap Gregory J Britt Daniel B Costa Michael S Rabin David M Jackman Bruce E Johnson

Clin Cancer Res 2010 Dec 28;16(23):5873-82. Epub 2010 Oct 28.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

 Source
http://clincancerres.aacrjournals.org/content/16/23/5873.ful
Web Search
http://clincancerres.aacrjournals.org/content/early/2010/10/
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-10-1588DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2999638PMC
December 2010

New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.

Authors:
Mizuki Nishino David M Jackman Hiroto Hatabu Beow Y Yeap Leigh-Anne Cioffredi Jeffrey T Yap Pasi A Jänne Bruce E Johnson Annick D Van den Abbeele

AJR Am J Roentgenol 2010 Sep;195(3):W221-8

Department of Radiology, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02116, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.2214/AJR.09.3928DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130298PMC
September 2010

Virginia Tech Carilion School of Medicine and Research Institute.

Authors:
Richard C Vari Terri F Workman Daniel P Harrington Timothy A Johnson James M Sherman Bruce E Johnson David B Trinkle Dennis E Means Cynda A Johnson

Acad Med 2010 Sep;85(9 Suppl):S582-5

View Article

Download full-text PDF

 Source
https://static.vtc.vt.edu/media/documents/2015-2016_Student_
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/ACM.0b013e3181ea9ec2DOI Listing
September 2010

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.

Authors:
Roy S Herbst Yan Sun Wilfried E E Eberhardt Paul Germonpré Nagahiro Saijo Caicun Zhou Jie Wang Longyun Li Fairooz Kabbinavar Yukito Ichinose Shukui Qin Li Zhang Bonne Biesma John V Heymach Peter Langmuir Sarah J Kennedy Hiroomi Tada Bruce E Johnson

Lancet Oncol 2010 Jul;11(7):619-26

Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX 77030-4009, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/S1470-2045(10)70132-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3225192PMC
July 2010

Parity and risk of lung cancer in women.

Authors:
Jessica K Paulus Kofi Asomaning Peter Kraft Bruce E Johnson Xihong Lin David C Christiani

Am J Epidemiol 2010 Mar 31;171(5):557-63. Epub 2010 Jan 31.

Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1093/aje/kwp441DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2842216PMC
March 2010

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Authors:
Mari Mino-Kenudson Lucian R Chirieac Kenny Law Jason L Hornick Neal Lindeman Eugene J Mark David W Cohen Bruce E Johnson Pasi A Jänne A John Iafrate Scott J Rodig

Clin Cancer Res 2010 Mar 23;16(5):1561-71. Epub 2010 Feb 23.

Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2845DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831135PMC
March 2010

ACP Journal Club. Estrogen plus progestin increased lung cancer mortality but not incidence in postmenopausal women.

Authors:
Bruce E Johnson Cynda A Johnson

Ann Intern Med 2010 Feb;152(4):JC-28

Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.7326/0003-4819-152-4-201002160-02008DOI Listing
February 2010

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Authors:
David Jackman William Pao Gregory J Riely Jeffrey A Engelman Mark G Kris Pasi A Jänne Thomas Lynch Bruce E Johnson Vincent A Miller

J Clin Oncol 2010 Jan 30;28(2):357-60. Epub 2009 Nov 30.

Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2009.24.7049DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3870288PMC
January 2010

Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.

Authors:
Emer O Hanrahan Heather Y Lin Edward S Kim Shaoyu Yan Danny Z Du Kathryn S McKee Hai T Tran J Jack Lee Anderson J Ryan Peter Langmuir Bruce E Johnson John V Heymach

J Clin Oncol 2010 Jan 30;28(2):193-201. Epub 2009 Nov 30.

University of Texas M. D., Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1200/JCO.2009.22.4279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040010PMC
January 2010

The Intermountain Risk Score, based on common laboratory tests, was highly predictive of short-term mortality.

Authors:
Bruce E Johnson

Evid Based Med 2009 Dec;14(6):186

Virginia Tech Carilion School of Medicine, Roanoke, Virginia, USA.

View Article

Download full-text PDF

 Source
http://ebm.bmj.com/cgi/doi/10.1136/ebm.14.6.186
Publisher Site
http://dx.doi.org/10.1136/ebm.14.6.186DOI Listing
December 2009

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Authors:
Peter S Hammerman Pasi A Jänne Bruce E Johnson

Clin Cancer Res 2009 Dec;15(24):7502-7509

Authors' Affiliations: Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, and Department of Medicine, Harvard Medical School, Boston, Massachusetts.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0189DOI Listing
December 2009

Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.

Authors:
Panos Fidias Nathan A Pennell Anthony L Boral Geoffrey I Shapiro Arthur T Skarin Joseph P Eder T Jesse Kwoh Richard S Geary Bruce E Johnson Thomas J Lynch Jeffrey G Supko

J Thorac Oncol 2009 Sep;4(9):1156-62

Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1097/JTO.0b013e3181b2793fDOI Listing
September 2009

Integration of molecular profiling into the lung cancer clinic.

Authors:
William Pao Mark G Kris A John Iafrate Marc Ladanyi Pasi A Jänne Ignacio I Wistuba Ryn Miake-Lye Roy S Herbst David P Carbone Bruce E Johnson Thomas J Lynch

Clin Cancer Res 2009 Sep 25;15(17):5317-22. Epub 2009 Aug 25.

Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.

View Article

Download full-text PDF

 Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-09-0913DOI Listing
September 2009

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.

Authors:
David M Jackman Vincent A Miller Leigh-Anne Cioffredi Beow Y Yeap Pasi A Jänne Gregory J Riely Marielle Gallegos Ruiz Giuseppe Giaccone Lecia V Sequist Bruce E Johnson

Clin Cancer Res 2009 Aug 11;15(16):5267-73. Epub 2009 Aug 11.

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0888DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219530PMC
August 2009

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

Authors:
Scott J Rodig Mari Mino-Kenudson Sanja Dacic Beow Y Yeap Alice Shaw Justine A Barletta Hannah Stubbs Kenny Law Neal Lindeman Eugene Mark Pasi A Janne Thomas Lynch Bruce E Johnson A John Iafrate Lucian R Chirieac

Clin Cancer Res 2009 Aug 11;15(16):5216-23. Epub 2009 Aug 11.

Department of Pathology, Brigham & Women's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0802DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865649PMC
August 2009